Opinion of the Transparency Council – tacrolimusum
At its meeting on 10 March 2025, the Transparency Council adopted opinion No. 42/2025 on the reimbursement of medicines containing the active substance tacrolimusum for indications, dosages or administration methods other than those specified in the Summary of Product Characteristics, i.e. myasthenia gravis